// App-Quantinova.ai

7004 : Clinical activity of ERY001 (erythrocyte encapsulated l-asparaginase) and native l-asparaginase (L-ASP) in combination with COOPRALL regimen in phase III randomized trial in patients with relapsed acute lymphoblastic leukemia (ALL).

Researchers

Presenter

  • Yves Bertrand

Principal Investigators

  • Andre Baruchel

  • Xavier G. Thomas

  • Genevieve Plat

  • Maryline Poiree

  • Jean-Louis Stephan

  • Anne Auvrignon

  • Dominique Plantaz

  • Isabelle Pellier

  • Cecile Bonin

  • Iman El-Hariry

  • Yves Perel

  • Norbert Vey

  • Virginie Gandemer

  • Victoria Cacheux

  • Francoise Mazingue

  • Emmanuel Raffoux

Medical Centers

  • Hematology, CHU Clermont Ferrand, Clermont-Ferrand, France

  • Hematology Saint Louis Hospital - APHP, Paris, France

  • Hospital Pediatric Hematology, Grenoble, France

  • Pediatric Hematology, AP-HP, GH HUEP, Trousseau Hospital, Paris, France

  • Hospital Pediatric Hematology, Grenoble, France

  • Pediatric Hematology, Childrens Hospital, Toulouse, France

  • Institut de Cancerologie Lucien Neuwirth, Saint-Priest en Jarez cedex, France.

  • Hematology Department, University Hospital, Nancy, France

  • ERYTECH Pharma, Lyon, France

  • Pediatric Hematology, Hopital Universitaire des Enfants Reine Fabiola, Universite Libre de Bruxelles, Brussels, Belgium

  • Hopital Universitaire Robert Debre, Paris, France

  • CHU Lenval, Nice, France

  • CHU Bordeaux, Bordeaux, FranceInstitut dHemato-Oncologie Pediatrique, Hospices Civils de Lyon, Lyon, France

  • Synta Pharmaceutical Corp., Boston, MA

  • Pediatric Hematology, Institut de Cancerologie de la Loire, Saint Priest En Jarez, France

  • Institut Paoli-Calmettes, Marseille, France

  • Centre Hospitalier Lyon Sud, Cedex, France

  • Pediatric Oncology, University Hospital, Lille, France

  • Hospital Pediatric Hematology, Grenoble, France

Locations

  • France

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Asparaginase

  • ERY001

Outcome

  • N/A

Study Design

  • randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved